Artiva Biotherapeutics (NASDAQ:ARTV) Releases Earnings Results, Misses Estimates By $0.24 EPS

Artiva Biotherapeutics (NASDAQ:ARTV) posted its quarterly earnings data on Tuesday. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.24), Zacks reports.

Artiva Biotherapeutics Stock Performance

NASDAQ ARTV traded down $0.49 on Thursday, reaching $11.21. 7,441 shares of the company were exchanged, compared to its average volume of 138,615. Artiva Biotherapeutics has a fifty-two week low of $9.68 and a fifty-two week high of $17.31. The firm has a fifty day simple moving average of $12.60.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Cantor Fitzgerald initiated coverage on shares of Artiva Biotherapeutics in a report on Tuesday, August 13th. They issued an “overweight” rating and a $23.00 price target for the company. Wedbush reiterated an “outperform” rating and set a $18.00 price target on shares of Artiva Biotherapeutics in a research note on Friday, August 30th. Jefferies Financial Group began coverage on Artiva Biotherapeutics in a research note on Tuesday, August 13th. They issued a “buy” rating and a $21.00 price objective for the company. TD Cowen initiated coverage on Artiva Biotherapeutics in a research report on Tuesday, August 13th. They issued a “buy” rating on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 price target on shares of Artiva Biotherapeutics in a research note on Wednesday. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Artiva Biotherapeutics presently has a consensus rating of “Buy” and an average target price of $21.25.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.